Clinical Trial: GV101 for Friedreich's Ataxia (FA) Treatment

U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07870590) titled 'GV101 for Friedreich's Ataxia (FA) Treatment' on Oct. 06.

Brief Summary: This is a dose-ranging, randomized, double-blind, placebo-controlled 12-week Phase 2a trial with an up to two week loading dose period. Eligible participants will be sequentially randomized 3:1 into three parallel groups, low-dose, mid-dose, and high-dose, to receive GV101 or placebo once daily for 12 weeks.

The low-dose group will receive 200 mg from Weeks 2-12 after a 100 mg loading dose at Week 1; the mid-dose group will receive 300 mg from Weeks 3-12 after loading doses of 100 mg and 200 mg at Weeks 1 and 2, respectively; and the high dose group will recei...